EN DE
Watch Meds Apotek AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Meds Apotek AB (MEDS) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Meds Apotek AB stock SEK 9.37, price SEK 23.80, that is 60.6% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Cyclical SE

MA Meds Apotek AB logo Some data Nov 9, 2026

Meds Apotek AB

MEDS · ST
Very expensive, in a downtrend

Our calculation puts a fair price 61% below what the stock costs today.

Low debt
Revenue last quarter +18% vs. a year ago.
Quality 55/100
Expensive Growth (revenue YoY +21.4 %/yr in SEK)
Thin margins · 1.4% net margin (TTM)
Mixed vs. peers (6/12)
Some data
Fair value kr 9.37 · Strongly overvalued
Negative free cash flow
Narrow moat 35/100
Watch Meds Apotek AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 58.00 kr 20.50 Fair Value kr 9.37 Sep 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

14‑month range kr 20.50 – kr 58.00 · fair‑value band kr 6.86 – kr 12.17 · the kr 23.80 price screens above the kr 9.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Meds Apotek in your weekly email

Every Wednesday you see whether Meds Apotek is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Meds Apotek AB operates as an online pharmacy that sells prescription and non-prescription medicines in Sweden.

Show moreShow less

The company offers various products, including beauty products, dietary supplements, children's products, facial care, vitamins and supplements, oral care for animals, pet accessories, fur care, allergy medicine, sunscreen and body sunscreen, eye mask, sleep mask, earplugs, hearing aids, contact lenses, fitness products, electric toothbrush, heat tools for hair, food and drinks, and home & household products.

The company was incorporated in 2016 and is based in Hägersten, Sweden.

Stock analysis

Meds Apotek AB (MEDS) currently trades at kr 23.80, while our model-based Fair Value estimate is kr 9.37, 61% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of kr 15.11 per share, and 1 of the 11 models we run sit above the kr 23.80 price.

Bear case: the Asset-Based group reads lowest at kr 4.70, and 10 of the 11 models stay below the price. Data coverage for this calculation is medium.

Scenario range: kr 6.86 (bear) to kr 12.17 (bull), the price of kr 23.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Consumer Cyclical sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Meds Apotek AB reported revenue of 1.0B SEK in FY2025 versus 655M SEK in FY2023, a compound +23.9%/yr. Reported net income was 7.7M SEK in FY2025.

Key figures

Market cap 442M SEK (≈ $44.3M) Micro · P/E ratio 31.7 · P/S ratio 0.41 · EPS (TTM) kr 0.7500 · Net margin 1.4% · Return on equity 14.8% · Return on assets (EBIT) −9.2% (3-year average) · Operating margin 1.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).

What moves the price

The share trades about 53% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at 19% fair-value upside, at −61%, MEDS screens richer than that median.

Fair Value models

Bear kr 6.86 Fair Value kr 9.37 Bull kr 12.17
Price kr 23.80 · Downside -60.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 0.6493 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA kr 11.00 kr 13.86 kr 16.71 67
Owner Earnings kr 8.15 kr 15.11 kr 29.18 65
Residual Income kr 5.37 kr 5.51 kr 5.93 64
All 11 models by family
DCF Models
Owner Earnings kr 8.15 kr 15.11 kr 29.18 65
Earnings-Based
Graham-Dodd kr 2.83 kr 19.73 kr 27.69 57
Lynch FV kr 6.56 kr 9.37 kr 12.17 55
PEG = 1.0 kr 6.56 kr 9.37 kr 12.17 52
Multiples
P/E Multiple kr 6.86 kr 9.15 kr 11.44 63
P/S Multiple kr 5.30 kr 7.07 kr 8.84 58
P/B Multiple kr 18.76 kr 25.01 kr 31.27 55
EV/EBITDA kr 11.00 kr 13.86 kr 16.71 67
Asset-Based
NCAV (Graham) kr 3.10 kr 4.70 kr 5.87 55
Economic Profit
Residual Income kr 5.37 kr 5.51 kr 5.93 64
Growth Earnings
Growth-Adj P/E kr 8.83 kr 12.61 kr 16.40 61

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 56
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 68
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 28
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

MEDS screens overvalued: fair value 61% below the price. Compare with Amazon.com, Inc →

Compare Meds Apotek AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Internet Retail · 119 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Below median
Fair Value upside −60.6% · Bottom 25%
Profitability
Return on equity (12 months) 14.8% · Above median
Return on assets 2.9% · Above median
Net margin (12 months) 1.4% · Above median
Operating margin (12 months) 1.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 17.6% · Above median

Valuation Multiplesvs Internet Retail median · lower = cheaper

P/E (12 months) 31.7× · Pricier than median
P/B 3.44× · Pricier than median
P/S (12 months) 0.41× · Cheaper than median
EV/EBITDA 60.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 37
FUTURE (revenue growth)88 · sector 58
PAST (return on equity)59 · sector 9
HEALTH (low debt)100 · sector 92
DIVIDEND (yield)0 · sector 64

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Internet Retail stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
PDD Holdings PDD $79.01 $237.03 +200% vs MEDS
Sea Limited SE $73.99 $129.32 +75% vs MEDS
Prosus N.V PRX €36.97 €52.04 +41% vs MEDS
MercadoLibre, Inc MELI $1,512 $1,830 +21% vs MEDS
Alibaba Group BABA $101.52 $120.38 +19% vs MEDS
DoorDash, Inc DASH $178.26 $199.06 +12% vs MEDS
Meituan 3690 HK$72.85 HK$60.39 −17% vs MEDS
Amazon.com, Inc AMZN $266.17 $140.05 −47% vs MEDS
eBay Inc EBAY $122.68 $60.00 −51% vs MEDS
Coupang, Inc CPNG $15.99 $4.98 −69% vs MEDS

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Meds Apotek AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Meds Apotek AB Fair Value". https://www.fairvalue-calculator.com/stock/MEDS

Frequently asked questions

Is Meds Apotek AB (MEDS) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of kr 9.37 versus a price of kr 23.80, about 61% lower (overvalued).
What is the fair value of MEDS?
Our model-based fair value for Meds Apotek AB is kr 9.37 (as of Nov 9, 2026), built from audited fundamentals. The current price: kr 23.80.
What is the quality score of MEDS?
Meds Apotek AB has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meds Apotek AB (MEDS)?
Our model-based price target is the fair value of kr 9.37 (as of Nov 9, 2026) from 11 valuation models. Cautious scenario kr 6.86, optimistic scenario kr 12.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Meds Apotek AB stock forecast for 2026?
Our models put fair value at kr 9.37, about 61% lower versus a price of kr 23.80 (overvalued). Cautious scenario kr 6.86, optimistic scenario kr 12.17. The calculation is refreshed regularly with new filings.
What is the revenue of Meds Apotek AB (MEDS)?
Meds Apotek AB reported trailing-twelve-month revenue of about 1.1B SEK (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Meds Apotek AB (MEDS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meds Apotek AB it is kr 9.37 per share (as of Nov 9, 2026), against a price of kr 23.80. It is the blended result of 11 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Meds Apotek AB stock overvalued or undervalued in 2026?
As of Nov 9, 2026, MEDS trades above its calculated fair value: price kr 23.80, fair value kr 9.37, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDS?
No. The price is what the market pays today (kr 23.80); the fair value is what the company's own numbers justify (kr 9.37). For Meds Apotek AB the two are kr 14.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Meds Apotek AB worth?
The market values Meds Apotek AB at about 442M SEK (market capitalisation, as of Nov 9, 2026). Per share that is kr 23.80; our models calculate a fair value of kr 9.37 per share.
What do the bullish and bearish scenarios say about MEDS?
Our models span a range for Meds Apotek AB: cautious scenario kr 6.86, base kr 9.37, optimistic kr 12.17 per share (as of Nov 9, 2026, price kr 23.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDS?
Meds Apotek AB trades at a price-to-earnings ratio of 31.7 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 9.37 is built from several models across several years. Other multiples: P/B 3.4, P/S 0.4, EV/EBITDA 60.1.
How solid is the balance sheet of Meds Apotek AB (MEDS)?
Balance-sheet figures for Meds Apotek AB (as of Nov 9, 2026): return on equity 14.8%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is MEDS from its 52-week high?
Meds Apotek AB trades at kr 23.80, about 53% below its 52-week high of kr 50.50 and 16% above the low of kr 20.50 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of kr 9.37 is for.
Which stocks are comparable to Meds Apotek AB?
From the same area (Consumer Cyclical) we also value Amazon.com, Inc, Alibaba Group, PDD Holdings, Prosus N.V, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meds Apotek AB stock attractive at the current price?
The data as of Nov 9, 2026: price kr 23.80, calculated fair value kr 9.37 (−61%), Quality Score 55/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDS calculated?
We run Meds Apotek AB through 11 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 9.37 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Meds Apotek AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meds Apotek AB (MEDS)?
The closing price on Nov 11, 2026 was kr 23.80. Our model-based fair value is kr 9.37, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meds Apotek AB right now?
The price sits above even our optimistic bull case (kr 12.17). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Meds Apotek AB

How large is the market capitalisation of Meds Apotek AB (MEDS)?
The market capitalisation of Meds Apotek AB is 442M SEK (≈ $44.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meds Apotek AB (MEDS)?
The price-to-sales ratio of Meds Apotek AB is 0.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Meds Apotek AB (MEDS)?
Earnings per share at Meds Apotek AB are kr 0.7500 (price ÷ EPS = P/E 31.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Meds Apotek AB (MEDS)?
The net margin of Meds Apotek AB is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meds Apotek AB (MEDS)?
The return on equity (ROE) of Meds Apotek AB is 14.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meds Apotek AB (MEDS)?
On an EBIT basis the return on assets of Meds Apotek AB is −9.2% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meds Apotek AB (MEDS)?
The operating margin of Meds Apotek AB is 1.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meds Apotek AB (MEDS)?
Revenue at Meds Apotek AB is growing +17.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Meds Apotek AB (MEDS)?
Earnings per share at Meds Apotek AB are growing −12.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Meds Apotek AB (MEDS) generate?
The free cash flow of Meds Apotek AB is −28.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Meds Apotek AB in the live analysis

One click puts Meds Apotek AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.